Superworth

Harvard Bioscience EV/EBIT HBIO

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026
n/m
an operating loss
Last meaningful
105×
May 2024
8-year median
59.4×
8-year range
28.6× to 229×
Peer median
7.8×

Harvard Bioscience has no meaningful EV/EBIT today: it made an operating loss of $245K over the last twelve months.

It was last meaningful in May 2024, at 105×.

On the days it had one over the last 8 years, its median was 59.4×, from 28.6× in Feb 2022 to 229× in Dec 2023.

EV/EBIT over time

The dashed line is the 8-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2024105×100×210×
2023227×177×229×
2022112×28.6×142×
202137.0×34.9×195×
2020139×31.1×218×
201956.0×38.4×226×
2018n/m a value too high to mean anything
2017n/m a value too high to mean anything
2016130×115×135×
2015149×24.4×159×
201428.6×26.0×41.8×
201332.8×12.6×34.0×
201212.4×10.9×14.2×

Against its peers

Companies in Healthcare nearest Harvard Bioscience's size, closest first, today.

CompanyEV/EBIT
HBIOHarvard Biosciencen/m
NEPHNephros20.5×
ATNMActinium Pharmaceuticals1.2×
APTAlpha Pro Tech8.2×
SPROSpero Therapeutics2.1×
LFVNLifevantage9.6×
ICCCImmucell14.2×
KEQUKewaunee Scientific7.2×
PDEXPro DEX16.0×
PLXProtalix BioTherapeutics7.5×
NATRNatures Sunshine Products5.2×
Peer median7.8×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Harvard Bioscience

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.